Pressure BioSciences and NutraLife Biosciences, a manufacturer and distributor of nutraceuticals primarily sold on a direct-to-consumer basis, have renewed collaborative efforts initiated four years ago.
Their fresh partnership is focused on combining PBIO's Best-in-Class UltraShear Nanoemulsification platform with NLBS's highly-effective nutraceuticals product formulation, marketing, sales, and distribution capabilities. The companies have just announced their fresh collaboration agreement, under which PBIO and NLBS will combine their strong, symbiotic capabilities to develop, market, and sell a higher-performing line of next-generation nutraceuticals.
Edgar Ward, President and CEO of NLBS, explained: "NutraLife is delighted to be once again working with PBIO. As we originally anticipated, their UltraShear technology platform has consistently proven to be superior to other nano technology platforms in multiple critical dimensions, including extended stability, with nearly complete effective water solubility, fast and reliable dose delivery, and vastly increased bioavailability."
Their revolutionary nanoemulsion process will allow us to greatly expand and differentiate our product offerings
- Edgar Ward, President and CEO of NLBS
Ward continued: "Their revolutionary nanoemulsion process will allow us to greatly expand and differentiate our product offerings, giving NLBS a distinct competitive advantage in the nutraceutical marketplace. The UltraShear process transforms products for greatly enhanced efficiency and effectiveness of absorption for targeted nutrients and therapeutic components, delivering the highest quality and reliable results for our consumers. The new "next generation" nutraceuticals that we plan to commercialise, utilising PBIO's innovative UltraShear platform, will be marketed and distributed through our expansive existing network of customers, on-line and retail distribution channels."
Richard Schumacher, President and CEO of PBIO, expanded: "Our UltraShear nanoemulsions platform has left initial collaborators across diverse markets awestruck over the potency and economic efficiencies that we can deliver to their customers and to their bottom line. Our priority has been to select partners who have the existing networks and infrastructure to "hit the ground running" with the uniquely differentiated, superior product opportunities that we offer and enable for them. Edgar and his team at NLBS are precisely what we seek - ready to leverage their extensive existing customer base and market channels to achieve early and rapidly scaling sales traction for innovative and re-engineered products across the nutraceuticals product frontier. In particular, they have been seeking a truly effective nano-CBD tincture solution - and we have that that product already developed and well proven in the hands of independent external experts."
As previously disclosed, PBIO initiated important bioavailability studies in both academic and commercial settings over the past year in an effort to support its claim that its revolutionary UltraShear technology platform is a "Best-in-Class" nanoemulsion processing method worldwide. The company is expecting results from at least one of these ongoing studies to be published in a peer-reviewed journal in the coming weeks.
Schumacher concluded: "Edgar and his team had the technical sophistication to understand and appreciate the power and potential of our UltraShear technology earlier than others, and our teams are now enthusiastically collaborating on several remarkable new product introductions. We expect these breakthrough innovative nutraceutical products to contribute incremental revenues in the millions of dollars for both PBIO and NLBS over the coming years, with substantial revenues for both companies beginning in 2023."